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Background: The gene encoding oestrogen receptor a (ESR1) appears to regulate bone mineral density
(BMD) and other determinants of osteoporotic fracture risk.
Objective: To investigate the relation between common polymorphisms and haplotypes of the ESR1 gene
and osteoporosis related phenotypes in a population based cohort of 3054 Scottish women.
Results: There was a significant association between a common haplotype ‘‘px’’, defined by the PvuII and
XbaI restriction fragment length polymorphisms within intron 1 of the ESR1 gene, and femoral neck bone
loss in postmenopausal women who had not received hormone replacement therapy (n = 945; p = 0.009).
Annual rates of femoral neck bone loss were ,14% higher in subjects who carried one copy of px and
22% higher in those who carried two copies, compared with those who did not carry the px haplotype. The
px haplotype was associated with lower femoral neck BMD in the postmenopausal women (p = 0.02), and
with reduced calcaneal broadband ultrasound attenuation (BUA) values in the whole study population
(p = 0.005). There was no association between a TA repeat polymorphism in the ESR1 promoter and any
phenotype studied, though on long range haplotype analysis subjects with a smaller number of TA repeats
who also carried the px haplotype had reduced BUA values.
Conclusions: The ESR1 px haplotype is associated with reduced hip BMD values and increased rates of
femoral neck bone loss in postmenopausal women. An association with BUA may explain the fact that
ESR1 intron 1 alleles predict osteoporotic fractures by a mechanism partly independent of differences in
BMD.
O
steoporosis is a common disease with a strong genetic
component, characterised by low bone mineral
density (BMD), microarchitectural deterioration of
bone tissue, and an increased risk of fracture.1 Although
BMD is the major predictor of osteoporotic fracture risk,2 3
quantitative ultrasound (QUS) properties of bone have
recently been found to predict osteoporotic fractures4
independent of BMD,5–7 showing that QUS provides informa-
tion about osteoporotic fracture risk beyond that which can
be obtained from BMD. This is thought to reflect the fact that
QUS provides information on bone structure and quality that
is distinct from BMD.8 Twin and family studies have shown
that BMD and QUS (measured by broadband ultrasound
attenuation and speed of sound) are under strong genetic
control.9–14 The genes responsible for regulating these
phenotypes are incompletely defined, but genetic linkage
studies have identified several quantitative trait loci for the
regulation of BMD15–19 and QUS.20 21 Moreover, polymorph-
isms in many candidate genes have been identified as
determinants of BMD and include the vitamin D receptor,22
oestrogen receptor a (ESR1),23 24 COLIA1,25 and TNFRSF1B,26
although much less information is available on candidate
genes for QUS regulation.
One of the most important and widely studied candidate
genes for osteoporosis is ESR1. While many polymorphism
have been described in ESR1, the most widely studied are a
dinucleotide repeat (TA) polymorphism located approxi-
mately 1.2 kb upstream from the first exon (dbSNP
id= rs3138774) and two single nucleotide polymorphisms,
located in the first intron, which are commonly detected by
restriction fragment length polymorphism assays using the
enzymes PvuII (rs2234693) and XbaI (rs9340799). Previous
association studies of these polymorphisms in relation to
BMD have yielded inconsistent results, probably because of
factors such as small sample size and differences between the
study populations in terms of age, menopausal status, and
ethnic background.23 27–35 Moreover, there is little information
on the possible association between ESR1 polymorphisms and
QUS values, or on the relation with postmenopausal bone
loss.29 36–39
In order to clarify the role of ESR1 as a candidate gene for
osteoporosis related phenotypes, we have investigated three
common polymorphisms and haplotypes of the ESR1 gene in
relation to BMD, bone loss, and QUS in a large population
based study of 3054 women from the north east of Scotland.
To our knowledge, this is the largest study investigating the
association between ESR1 gene polymorphisms and bone
characteristics in women from an ethnically homogeneous
population.
METHODS
Study subjects
The study group comprised white women who were
randomly selected from the community health index, a
database of all patients registered with a general practitioner
from a 25 mile radius of Aberdeen, a city in the north east of
Scotland, as part of a large prospective population based
screening programme for osteoporotic fracture risk (the
APOSS study).40 The screening programme involved approxi-
mately 7000 women who were invited by letter to undergo
Abbreviations: APOSS, Aberdeen prospective osteoporosis screening
study; BMD, bone mineral density; BMI, body mass index; BUA,
broadband ultrasound attenuation; HRT, hormone replacement therapy;
LRH, long range haplotype; QUS, quantitative ultrasound; SNP, single
nucleotide polymorphism
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bone mineral density (BMD) measurements between 1990
and 1994. In all, 5119 women (,73%) attended for
evaluation and underwent BMD measurement at the lumbar
spine and femoral neck and completed a risk factor
questionnaire. This included details of fracture history,
menopausal status, and use of hormone replacement therapy
(HRT). Participants were weighed on a set of balance scales
calibrated to 0.05 kg (Seca, Hamburg, Germany) and height
was measured using a stadiometer (Holtain, Crymych, Dyfed,
UK). All women were invited to undergo further assessment
between 1997 and 1999, and 3882 women (75.8%) re-
attended for evaluation. Baseline investigations were
repeated at the follow up visit and information was gathered
on fracture history by completion of a questionnaire.
Calcaneal broadband ultrasound attenuation and speed of
sound was measured and blood samples were obtained for
DNA extraction from 3054 women who consented. Women
were classified as premenopausal if they were menstruating
regularly, as perimenopausal if menstruation was irregular
and/or up to six months had elapsed since their last period,
and postmenopausal if menstruation had ceased for six
months or more. Information gathered on menopausal status
and HRT use identified five categories as follows: 1,
premenopausal, no HRT; 2, perimenopausal, no HRT; 3,
postmenopausal, no HRT; 4, postmenopausal, previous HRT
user; 5, postmenopausal, current HRT user.
Fracture assessment at the baseline visit (prevalent
fractures) was based on the questionnaire, whereas fracture
data obtained at the follow up visit (incident fractures
occurring between baseline and follow up) were confirmed
by scrutiny of hospital records and x ray reports. Owing to the
young age of the study subjects, the number of incident
fractures observed in this population was small (nine hip
fractures and 15 clinical vertebral fractures). Because of this,
we did not analyse the relation between ESR1 polymorphisms
and fractures in this study. All participants gave written
informed consent to be included in the study, which was
approved by the Grampian research ethics committee.
Bone mineral densitometry measurements
BMD measurements of the left proximal femur (femoral
neck) and lumbar spine (L2–L4) were carried out by dual
energy x ray absorptiometry using one of two Norland XR26
or XR36 densitometers (Norland Corporation, Fort Atkinson,
Wisconsin, USA). Calibration of the machines was under-
taken daily, and quality assurance checked by measuring the
manufacturer’s lumbar spine phantom at daily intervals and
a Hologic spine phantom at weekly intervals. The in vivo
precision for XR26 was 1.95% for lumbar spine, and 2.3% for
femoral neck. Corresponding values for the XR36 were 1.2%
for lumbar spine and 2.3% for femoral neck. Comparison
between the XR26 and XR36 was made using 50 phantom
spine measurements from each machine. The XR36 was
consistently found to give slightly higher measurements
(2.4%) than the XR26. BMD measurements obtained from
the XR36 were therefore corrected to correspond with the
XR26 by regression analysis.
Quantitative ultrasound measurements
Quantitative ultrasound (QUS) measurements were carried
out using a Hologic Sahara scanner (Hologic Inc, Bedford,
Massachusetts, USA). This measures speed of sound (SOS,
m/s) and broadband ultrasound attenuation (BUA, dB/MHZ),
by assessing the ‘‘loss’’ of sound waves as they travel across
the calcaneus. This is a dry system where transducers are in
direct contact with the skin, and an oil based gel is used as a
coupling device. In vitro precision (coefficient of variation) in
our hands is less than 1% when examining 10 phantoms.
Genotyping
Genomic DNA was extracted from peripheral blood leuco-
cytes using the Nucleon II DNA extraction kit (Scotlab,
Coatbridge, Lanarkshire, UK) according to the manufac-
turer’s instructions. The PvuII and XbaI polymorphisms are
45 bp apart and located approximately 400 bp upstream of
exon 2. Genotypes for the PvuII and XbaI polymorphisms
Table 1 Characteristics of the study subject at baseline and follow up according to menopausal status and use of hormone
replacement therapy
Characteristic
Baseline Follow up
Total study
population
Total study
population
Postmenopausal, no
HRT
Postmenopausal HRT
users
Pre- and
perimenopausal
Number 3054 3054 945 (30.9%) 1802 (59.0%) 307 (10.1%)
Age (years) 48.5 (2.3) 54.7 (2.2) 55.0 (2.2) 54.8 (2.2) 53.0 (1.5)
Body mass index (kg/m2) 25.3 (4.4) 26.5 (4.7) 26.8 (4.8) 26.3 (4.6) 27.0 (5.0)
LS BMD (g/cm2) 1.051 (0.160) 1.009 (0.168) 0.990 (0.160) 1.004 (0.166) 1.099 (0.175)
FN BMD (g/cm2) 0.880 (0.125) 0.837 (0.123) 0.831 (0.120) 0.832 (0.122) 0.886 (0.124)
Changes in LS BMD (%/year) – 20.614 (1.223) 21.337 (1.048) 20.322 (1.186) 20.084 (0.932)
Changes in FN BMD (%/year) – 20.745 (1.059) 21.210 (1.016) 20.558 (1.020) 20.401 (0.945)
Calcaneal BUA (dB/MHz)* – 75.5 (17.0) 73.2 (17.3) 76.1 (16.8) 79.0 (16.4)
Calcaneal SOS (m/s)* – 1553.1 (32.8) 1548.2 (31.2) 1554.1 (32.7) 1561.5 (34.5)
Time since menopause (years) 2.3 (4.5) 5.7 (6.3) 6.3 (5.0) 6.3 (6.9) –
Follow up time (years) – 6.2 (0.7) 6.2 (0.7) 6.3 (0.8) 6.1 (0.7)
Data are mean (SD).
*Data for broadband ultrasound attenuation (BUA) and speed of sound (SOS) at the calcaneus were available for 2449 subjects at follow up visit (742
postmenopausal women who were not HRT users, 1465 HRT users, and 242 pre- and perimenopausal women).
BMD, bone mineral density; BUA, broadband ultrasound attenuation; FN, femoral neck; HRT, hormone replacement therapy; LS, lumbar spine; SOS, speed of
sound.
Table 2 Distribution of long range haplotypes defined
by the TA repeat, PvuII and XbaI polymorphisms in the
study population
Long range haplotype
Number of
alleles (%)(TA)n repeat allele* PvuII-XbaI LRH code
L PX I 185 (3.38)
L Px II 157 (2.87)
L pX III 18 (0.33)
L px IV 2579 (47.17)
H PX V 1693 (30.96)
H Px VI 505 (9.24)
H pX VII 24 (0.44)
H px VIII 307 (5.61)
*The (TA)n alleles were classified as L if n(18, and H if n.18.
LRH, long range haplotype.
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were determined by direct DNA sequencing. A 346 bp
polymerase chain reaction (PCR) product containing both
polymorphic sites was amplified by PCR as described
previously.32 PCR products were then cleaned using ExoSAP
ITTM kit (USB Corp, Cleveland, Ohio, USA) and sequenced
using the DYEnamic ET dye terminator cycle sequencing kit
(Amersham Pharmacia Biotech UK, Buckinghamshire, UK).
DNA sequencing was carried out in 96-well plates which
were run on a MEGABACE-1000 automated DNA sequencer
(Amersham Pharmacia Biotech). The genotypes were repre-
sented as Pp (PvuII) and Xx (XbaI), with upper case letters
signifying the absence of, and lower case letters the presence
of, the restriction site.
The TA repeat polymorphism of the ESR1 gene was
investigated by PCR using a FAM labelled forward primer
(59-FAM-GACGCATGATATACTTCACC-39) and reverse pri-
mer (59-GCAGAATCAAATATCCAGATG-39) in a 25 ml PCR
reaction containing: 2.5 ml 10X PCR buffer (Qiagen, Crawley,
E Sussex, UK), 2.0 ml of dNTP (10 mM each), 5.0 ml of Q
solution, 2.5 ml of oligonucleotide primer mix (5 mM each of
forward and reverse primer), 0.125 ml of 5 U/ml Taq DNA
polymerase (Qiagen), and 50–100 ng genomic DNA. The
reaction volume was made up to 25 ml using deionised water.
The following thermal cycling conditions were used on a
Gene Engine thermocycler (MJ Research Inc, Watertown,
Massachusetts, USA): one cycle of (94 C˚ for four minutes,
58 C˚ for 30 seconds, 72 C˚ for 30 seconds) followed by 30
cycles of (94 C˚ for 30 seconds, 58 C˚ for 30 seconds, 72 C˚ for
30 seconds). The length of PCR product was determined by
analysis on a MEGABACE-1000 using the Genetic ProfilerTM
software (Amersham Pharmacia Biotech). Genotypes were
scored independently by two different individuals. To check
for genotyping errors, 50 DNA samples were selected
randomly and reanalysed. All genotypes were identical to
those obtained from the first round analysis. The genotyping
success rate was 94% for PvuII and XbaI and 96% for TA
repeat polymorphism. Our genotyping method for TA repeat
was found to estimate systematically one less TA repeat than
the method used by researchers who also studied this
polymorphism in a cohort of individuals from the
Rotterdam study.32 This was found by independent genotyp-
ing of 50 samples from our population carried out by the
Rotterdam research group.32
Statistical analysis
Haplotypes were inferred from genotype data using the
PHASE software program.41 The probability of the PvuII-XbaI
haplotype phase being correctly inferred was .0.99, and the
average probability for the TA-PvuII-XbaI haplotype being
correctly inferred was 0.987 (95% confidence interval, 0.983
to 0.991). Statistical analyses were carried out using SPSS
version 10.0 (SPSS Inc, Chicago, Illinois, USA). Differences in
BMD, BUA, and bone loss between the genotype and
haplotype groups were tested using analysis of covariance
(ANCOVA) to adjust for confounding factors such as age,
body mass index (BMI), BMD, menopausal status, and HRT
use. For the haplotype analysis, study subjects were coded
according to whether they had two copies, one copy, or no
copies of the haplotype under investigation. Multiple linear
regression analysis was used to test for gene dose effects.
Power calculations indicated that the study had .97% power
to detect differences in BMD and BUA of 0.1 SD units
between genotypes assuming a minor allele frequency of
30%. Probability (p) values of ,0.05 were considered
significant. We also used a modified Bonferroni correction42
to adjust for the number of independent tests carried out,
taking into account that the three polymorphisms are in
strong linkage disequilibrium and the variables tested are
strongly correlated with each other. The corrected threshold
of significance was p,0.015. As it has been argued that the
Bonferroni correction may be too conservative,43 we present
the unadjusted p values in the text.
RESULTS
Characteristics of study population
Table 1 shows relevant demographic characteristics of the
study population at the baseline and follow up visits. The
average age of the study subjects was 48.5 years at baseline,
and at this time 46.3% of women were postmenopausal. The
average age at the follow up visit was 54.7 years and the
Table 3 Relation between bone phenotypes and ESR1 alleles in the whole study
population
Characteristic
ESR1 polymorphism ESR1 haplotype
TA repeat PvuII XbaI px L-p-x
Baseline LS BMD
Crude 0.44 0.97 0.79 0.91 0.62
Adjusted 0.47 0.98 0.73 0.99 0.71
Baseline FN BMD
Crude 0.90 0.77 0.82 0.71 1.00
Adjusted 0.92 0.88 0.77 0.75 0.88
Changes in LS BMD
Crude 0.82 0.17 0.72 0.36 0.62
Adjusted 0.96 0.48 0.97 0.74 0.76
Changes in FN BMD
Crude 0.37 0.59 0.69 0.31 0.09
Adjusted 0.34 0.27 0.48 0.15 0.06
Calcaneal BUA
Crude 0.37 0.004 0.58 0.003 0.002
Adjusted 0.42 0.009 0.66 0.010 0.008
Calcaneal SOS
Crude 0.45 0.08 0.99 0.07 0.012
Adjusted 0.57 0.14 0.95 0.14 0.023
Values presented are p values obtained from analysis of variance for crude data and analysis of covariance for the
adjusted data. Lumbar spine and femoral neck bone mineral density (BMD) values were adjusted for age, body
mass index (BMI), menopausal status, and hormone replacement therapy (HRT) use. Change in BMD values are
presented as per cent per year and were adjusted for age, BMI, change in BMI, baseline BMD, menopausal status,
and HRT use. Broadband ultrasound attenuation (BUA) and speed of sound (SOS) values were adjusted for age,
BMI, BMD, menopausal status, and HRT use.
FN, femoral neck; LS, lumbar spine.
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majority of women were postmenopausal (89.9%). Values for
age, BMI, lumbar spine BMD, and femoral neck BMD at the
baseline visit were, as expected, significantly different from
those at the follow up visit (p,0.001). The average bone loss
per year over the 6.2 years follow up was 0.61% and 0.74% at
lumbar spine and femoral neck, respectively. Table 1 also
shows BMD and QUS values in the study population
according to menopausal status and HRT use. At the follow
up visit, 59% of the women were either current or previous
HRT users. There was a significant association between HRT
use and age at menopause, so that subjects who were current
HRT users had earlier age at menopause (mean (SD), 44.6
(8.6) year) than those with previous HRT treatment (46.5
(6.6) years) or those without HRT treatment (48.4 (5.7)
years) (p,0.001).
Genotype and haplotype frequencies
On DNA sequencing analysis, we were only able to detect the
PvuII and XbaI polymorphisms in our population, even
though single nucleotide polymorphisms (SNP) databases
suggest the presence of four additional SNPs in the
sequenced region. We conclude therefore that these SNPs
are absent or very rare in our population. The genotype
frequencies for the PvuII and XbaI polymorphisms were:
PP=643 (22.4%), Pp=1383 (48.2%), pp=845 (29.4%),
XX=347 (12.1%), Xx=1328 (46.3%), and xx=1193
(41.6%). These were in Hardy–Weinberg equilibrium and
are similar to those previously reported in white popula-
tions.29 30 35 The PvuII-XbaI haplotype frequencies were:
PX=1960 (34.5%), Px=685 (12.0%), pX=47 (0.8%), and
px=2998 (52.7%). There was strong linkage disequilibrium
between PvuII and XbaI polymorphisms (D9=0.956,
p,0.000001) and two common haplotypes (PX and px)
accounted for 87.1% of alleles defined by these two
polymorphisms, as previously reported in white popula-
tions.30 31 For the TA repeat polymorphism, we observed 23
different alleles with TA repeat number ranging between 8
and 30 (supplementary figure; see on the JMG website at
www.jmedgenet.com/supplemental). This polymorphism
showed a bimodal distribution, with two peaks at 15 repeats
(31.6% of alleles) and 24 repeats (10.2% of alleles), and a
breakpoint at 18 TA repeats as reported previously.30–32
For statistical analysis, TA repeat alleles were classified into
two groups on the basis of whether the number of repeats
was above the breakpoint (‘‘H alleles’’; .18 repeats) or below
(‘‘L alleles’’;(18 repeats). When divided upon this basis, the
TA repeat genotype frequencies were LL=867 (29.5%);
LH=1433 (48.7%); and HH=643 (21.8%). Strong linkage
disequilibrium was observed between TA repeat and PvuII-
XbaI polymorphisms, such that low numbers of TA repeats
(L) were in strong linkage disequilibrium with the ‘‘p’’ allele
of the PvuII polymorphism (D9=0.755; p,0.000001) and
the ‘‘x’’ allele of the XbaI polymorphism (D9=0.803;
p,0.000001). Long range haplotypes (LRH) defined by the
TA, PvuII, and XbaI polymorphisms are shown in table 2. All
eight possible haplotypes were found, and two common
ones—‘‘L-p-x’’ (47.17%) and ‘‘H-P-X’’ (30.96%)—accounted
for 78.13% of the alleles observed, in keeping with those
reported previously in elderly Dutch subjects.32
Association between ESR1 alleles and osteoporosis
related phenotypes
We found no significant association between any of the ESR1
polymorphisms or haplotypes and BMD at the lumbar spine
or femoral neck at baseline in the whole study population, or
with annual rates of bone loss (table 3). Similarly, we found
no association between ESR1 alleles and other confounding
variables such as age, BMI, or age at menopause (data not
shown).
Analysis of PvuII-XbaI haplotypes in relation to calcaneal
QUS at follow up showed that BUA values were significantly
reduced in subjects carrying the px haplotype (mean (SEM)
BUA, 75.0 (0.4); n=1743) compared with those without this
haplotype (77.1 (0.7); n=532) (p=0.005). The results
remained significant after adjusting BUA values for age,
BMI, BMD, menopausal status, and HRT use (px BUA=75.0
(0.4); no px BUA=77.2 (0.7)) (p=0.006). A similar trend
was observed for calcaneal speed of sound (SOS) but the
results were of borderline significance (table 3). There was no
significant association between the TA repeat polymorphism
and BUA except when the data were analysed as long range
haplotype with the intron 1 polymorphisms, when we
observed reduced BUA and SOS values in carriers of the
L-p-x haplotype (BUA=74.8 (0.4); SOS=1551.9 (0.8);
n=1570) compared with subjects who did not carry this
haplotype (BUA=77.2 (0.7); SOS=1555.6 (1.3); n=618)
(p=0.003 and 0.018, respectively). This result remained
statistically significant after adjusting for age, BMI, BMD,
menopausal status, and HRT use (L-p-x BUA=74.9 (0.4), no
L-p-x BUA=77.0 (0.6); L-p-x SOS=1552.2 (0.8), no L-p-x
SOS=1555.4 (1.2)) (p=0.005 and 0.019, respectively).
Table 4 Association between ESR1 alleles, follow up bone mineral density, and bone loss
in postmenopausal women who were not taking hormone replacement therapy
Characteristic
Number of copies of px haplotype
p Value0 1 2
Number of cases 212 433 231
LS BMD
Crude 0.995 (0.012) 0.998 (0.008) 0.967 (0.009) 0.042
Adjusted 0.996 (0.011) 0.997 (0.007) 0.969 (0.010) 0.067
FN BMD
Crude 0.842 (0.009) 0.833 (0.006) 0.811 (0.007) 0.014
Adjusted 0.842 (0.008) 0.833 (0.005) 0.814 (0.007) 0.019
LS BMD change
Crude 21.273 (0.072) 21.348 (0.052) 21.382 (0.063) 0.532
Adjusted 21.273 (0.068) 21.356 (0.048) 21.363 (0.066) 0.549
FN BMD change
Crude 21.063 (0.069) 21.231 (0.052) 21.274 (0.057) 0.066
Adjusted 21.051 (0.065) 21.204 (0.046) 21.286 (0.062) 0.030
Values are mean (SEM).
Lumbar spine and femoral neck bone mineral density (BMD) values were adjusted for age, body mass index (BMI),
and years since menopause; change in BMD values (per cent per year) were adjusted for age, BMI, change in BMI,
baseline BMD, and years since menopause.
FN, femoral neck; LS, lumbar spine.
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In view of the fact that HRT is known to have a profound
influence on bone loss, we investigated annual rates of bone
loss in the subgroup of women who were or had become
postmenopausal at the second visit and who had not taken
HRT (table 1). As expected, these women lost more bone than
premenopausal women and HRT users. No difference was
observed in distribution of ESR1 polymorphisms or haplo-
types in these three groups (data not shown). A significant
association was found between the px haplotype and bone
loss at the femoral neck in postmenopausal women not
taking HRT, however, and this remained significant after
adjustment for age, BMI, changes in BMI, baseline BMD, and
years since menopause (table 4).
There was clear evidence of a gene dose effect, such that
the annual percentage fall in femoral neck BMD increased by
11.8% per copy of the px haplotype (p=0.009). When the
analysis was repeated using information from the TA repeat
polymorphism, the same trends were observed for the L-p-x
haplotype but the result was not significant (p=0.06).
Analysis of BUA in the non-HRT users showed that subjects
with two copies or one copy of the px haplotype had lower
BUA values (73.1 (0.7); n=518) than those without this
haplotype (73.8 (1.3); n=166), but this difference was not
significant (p=0.60), possibly because the number of
individuals with BUA data in the non-HRT user group was
small (684) compared to the total study population (2275). In
keeping with this, we estimated that a subgroup size of more
than 1250 would be required to attain 90% power to detect
the difference in BUA observed between the genotype groups
in the whole study population (0.14 SD units).
Analysis of ESR1 polymorphisms in the HRT user group
showed a significant association between the px haplotype
and BUA so that subjects with one or two copies of the px
haplotype had lower adjusted BUA values (75.3 (0.5);
n=1043) than those without this haplotype (78.7 (0.9);
n=318) (p=0.001) and no association was found between
any ESR1 genotype or haplotype and BMD or its annual
changes in this subgroup. ESR1 polymorphisms were not
associated with any bone related phenotype in the pre- and
perimenopausal subgroup.
DISCUSSION
The ESR1 gene encoding the oestrogen receptor a is a strong
candidate for the genetic regulation of bone mass, bone
remodelling, and postmenopausal bone loss. However,
studies of ESR1 alleles in relation to BMD have yielded
inconsistent results,23 27–38 possibly because most studies have
been of small sample size and involved subjects of different
ages, menopausal status, and ethnic background. In this
study, we investigated the relation between ESR1 polymorph-
isms and several phenotypes relevant to the pathogenesis of
osteoporotic fractures in a large population based cohort
study of white women from Scotland who had been
prospectively followed for an average of 6.2 years. While we
observed no association between ESR1 alleles and BMD or
bone loss in the whole study population, there was a
significant association between the px haplotype and rates
of bone loss at the femoral neck in postmenopausal women
who had not taken HRT. The annual rates of femoral neck
bone loss were about 14% higher in subjects who carried one
copy of px and 22% higher in those carrying two copies
compared with individuals who did not carry the px
haplotype. Reflecting this, we also detected an association
between the px haplotype and femoral neck BMD in this
subgroup of women, such that femoral neck BMD values
were 1% lower in px heterozygotes and 3% lower in px
homozygotes at follow up than in subjects who did not carry
the px allele.
We also found a strong association between the px allele
and broadband ultrasound attenuation at the calcaneus. This
was observed in the whole study population and HRT users,
and the association remained significant after adjusting for
BMD and confounding factors such as age, BMI, and
menopausal status. While the association we observed
between calcaneal SOS and ESR1 polymorphisms was much
weaker, previous studies in a large white cohort have shown
that BUA is a better predictor of fracture risk than SOS.5 The
association between BUA and the px allele in non-HRT users
did not reach statistical significance although this could have
reflected the small sample size of this subgroup.
There have been few previous studies of ESR1 polymorph-
isms in relation to quantitative ultrasound properties of bone.
Those that have been done showed an association between
the ESR1 XbaI polymorphism and calcaneal quantitative
ultrasound (QUS) indices in young white women aged 18
to 35 years37 and in Korean postmenopausal women.38 While
neither of these groups carried out haplotype analysis, both
studies reported reduced QUS values (stiffness index and
BUA) in association with the x allele, which is in broad
agreement with the findings reported here, where the px
haplotype was associated with reduced BUA. In another
study, no association was observed between the XbaI
polymorphism and calcaneal QUS in postmenopausal women
taking HRT,36 although the sample size in that study was
about one fifth as large as the population described here.
The present study is the first to investigate haplotypes of all
three ESR1 polymorphisms in relation to BUA and the first to
report an association with calcaneal BUA independent of
BMD. The association we observed with BUA is of relevance
in light of a recent meta-analysis which showed that carriers
of the XX genotype had a substantially reduced risk of
osteoporotic fractures (odds ratio 0.66) when compared with
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Figure 1 Evolutionarily conserved regions in the human ESR1 gene compared with the mouse (upper panel) and rat (lower panel) genome. E1 and
E2, exons 1 and 2. The first intron spans approximately 34 kb and is shown as a black box (http://ecrbrowser.dcode.org/).
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xx homozygotes, and that this was out of proportion to the
relatively small association between the XbaI polymorphism
and BMD (approximately 0.15 g/cm2).24 This raises the
possibility that ESR1 polymorphisms might influence fracture
risk by an effect on bone quality that is captured by BUA
measurements but not by BMD measurements.6
In a previous study of older postmenopausal women
derived from the same region of the United Kingdom (mean
age, 64.4 years), we observed an association between Px
haplotype and BMD. These results were based on a small
sample size (n=206), however, and emphasise the impor-
tance of carrying out large scale studies for the genetic
dissection of complex traits such as BMD.31 The association
we observed in the present study between the px haplotype
and increased rates of postmenopausal bone loss is in broad
agreement with the findings previously reported in a cohort
of elderly women from the Rotterdam study, where the px
haplotype was associated with reduced lumbar spine BMD
and an increased risk of vertebral fracture.32 While these
investigators did not investigate allelic associations with bone
loss, our data would be consistent with the hypothesis that
ESR1 alleles regulate BMD by affecting bone loss rather than
peak bone mass. The fact that the association we observed
was restricted to a group of postmenopausal women who had
not taken HRT is expected, given the known protective
influence of HRT on rates of bone loss. In view of this, we
speculate that under conditions of oestrogen sufficiency—
such as in premenopausal women and HRT users—the
association between ESR1 polymorphisms and bone turnover
may be masked but may become progressively more apparent
with increasing age in postmenopausal women who are
oestrogen deficient.
The association we observed between ESR1 polymorphisms
and bone loss was stronger for femoral neck than for lumbar
spine. Although lumbar spine would be expected to be the
more sensitive site to changes in HRT, the associated site may
vary between different populations. Previous meta-analysis
of ESR1 polymorphisms showed differences in the skeletal
site associated with ESR1 polymorphisms among the different
populations, and when all populations were analysed
together the study showed equal effect of ESR1 alleles on
lumbar spine and femoral neck BMD.24
There has previously been controversy over whether the
associations between BMD and polymorphisms in the 59
region of the ESR1 gene are driven by the intron 1
polymorphisms or the TA repeat polymorphism in the ESR1
promoter. Some investigators have reported that the TA
repeat polymorphism is primarily responsible for driving the
association with BMD,30 32 whereas others, including our own
group, have reported that the association is driven by the
intron 1 alleles.23 31 In the present study we found no
significant association between the ESR1 TA repeat poly-
morphisms and bone related phenotypes except on long
range haplotype analysis, where subjects with a low number
of TA repeats who had carried the px haplotype were found to
have reduced BUA values. Although this suggests that in our
population the association we observed was primarily driven
by the px haplotype, it is difficult to be confident about this,
given the strong linkage disequilibrium that exists between
these polymorphisms.
While ESR1 is one of the most intensively studied candidate
genes for osteoporosis susceptibility, the mechanisms that
underlie the associations between bone phenotypes remain
unclear. Previous studies have shown that the PvuII poly-
morphism lies within consensus recognition sites for the AP4
and Myb transcription factors.31 44 Studies using promoter-
reporter assays have shown that the PvuII polymorphism
influences Myb driven transcription in vitro,44 and other
studies have shown that both XbaI and PvuII polymorphisms
also influence reporter gene transcription in vitro.45 In this
regard, it is of interest that the PvuII and XbaI polymorphisms
are located within a region that is 70–80% conserved in the
human, mouse, and rat genomes, whereas the TA repeat
polymorphism is not conserved to any significant extent across
species (fig 1). While our observations would be consistent
with a direct functional effect of the PvuII and XbaI
polymorphisms on ESR1 gene transcription we cannot exclude
the possibility that these polymorphisms are in linkage
disequilibrium with causal polymorphisms elsewhere in the
ESR1 gene. Further functional analysis will be required to
investigate this possibility.
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